Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Japan MHLW
Pharma
Daiichi Sankyo bags an industry first for blood cancer drug
The go-ahead makes Ezharmia the first dual EZH1/2 inhibitor to receive regulatory approval anywhere in the world.
Angus Liu
Sep 26, 2022 11:02am
Biogen, Eisai get Aduhelm no-go in Japan
Dec 22, 2021 9:45am
Junshi, Novartis, Roche, Hanmi—Fierce Pharma Asia
Jul 23, 2021 4:49am
Gilead's RA drug filgotinib wins global-first nod in Japan
Sep 25, 2020 11:18am
Gilead's remdesivir, Lilly-Junshi and more—FiercePharmaAsia
May 8, 2020 9:55am
Opdivo price cut may be just the beginning as Japan looks to expedite drug pricing reviews
Dec 12, 2016 10:00am
